1. Home
  2. WNEB vs LCTX Comparison

WNEB vs LCTX Comparison

Compare WNEB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WNEB
  • LCTX
  • Stock Information
  • Founded
  • WNEB 1853
  • LCTX 1990
  • Country
  • WNEB United States
  • LCTX United States
  • Employees
  • WNEB N/A
  • LCTX N/A
  • Industry
  • WNEB Savings Institutions
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WNEB Finance
  • LCTX Health Care
  • Exchange
  • WNEB Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • WNEB 189.6M
  • LCTX 110.2M
  • IPO Year
  • WNEB N/A
  • LCTX N/A
  • Fundamental
  • Price
  • WNEB $8.68
  • LCTX $0.55
  • Analyst Decision
  • WNEB Hold
  • LCTX Strong Buy
  • Analyst Count
  • WNEB 3
  • LCTX 5
  • Target Price
  • WNEB $8.50
  • LCTX $4.80
  • AVG Volume (30 Days)
  • WNEB 39.5K
  • LCTX 2.9M
  • Earning Date
  • WNEB 01-21-2025
  • LCTX 03-06-2025
  • Dividend Yield
  • WNEB 3.23%
  • LCTX N/A
  • EPS Growth
  • WNEB N/A
  • LCTX N/A
  • EPS
  • WNEB 0.52
  • LCTX N/A
  • Revenue
  • WNEB $72,500,000.00
  • LCTX $8,719,000.00
  • Revenue This Year
  • WNEB N/A
  • LCTX N/A
  • Revenue Next Year
  • WNEB $6.24
  • LCTX $41.15
  • P/E Ratio
  • WNEB $16.76
  • LCTX N/A
  • Revenue Growth
  • WNEB N/A
  • LCTX N/A
  • 52 Week Low
  • WNEB $6.00
  • LCTX $0.48
  • 52 Week High
  • WNEB $10.08
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • WNEB 34.73
  • LCTX 47.26
  • Support Level
  • WNEB $8.51
  • LCTX $0.51
  • Resistance Level
  • WNEB $9.22
  • LCTX $0.60
  • Average True Range (ATR)
  • WNEB 0.18
  • LCTX 0.04
  • MACD
  • WNEB -0.08
  • LCTX 0.01
  • Stochastic Oscillator
  • WNEB 20.24
  • LCTX 53.85

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: